Literature DB >> 7692581

Evolution of surgery in the treatment of hepatocellular carcinoma from the 1950s to the 1990s.

Z Y Tang1, Y Q Yu, X D Zhou.   

Abstract

In the 1950s, hepatic lobectomy for huge hepatocellular carcinoma (HCC) has benefited 5-10% of HCC patients; in the 1970s, limited resection for small HCC and reresection for recurrence have benefited another 5-10% HCC patients. Cytoreduction and sequential resection for unresectable HCC might be of benefit to a further 5-10% HCC patients in the 1990s. Analysis of 1,642 patients with pathologically proven HCC in 1959-1991 demonstrated that the series 5-year survival has increased from 3.0% (n = 136) in the 1960s, to 12.2% (n = 440) in the 1970s, to 40.2% (n = 1,066) in the 1980s, which was correlated to the increasing number of limited resections for small HCC, reresections for subclinical recurrence, and cytoreductions and sequential resections for portions of unresectable HCC. With the advances in early detection, multimodality treatment, and changing concepts in surgical oncology, the role of surgery in the treatment of HCC has increased.

Entities:  

Mesh:

Year:  1993        PMID: 7692581     DOI: 10.1002/ssu.2980090403

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN: 1098-2388


  6 in total

1.  High-intensity focused ultrasound in the treatment of experimental liver tumour.

Authors:  S Q Cheng; X D Zhou; Z Y Tang; Y Yu; H Z Wang; S S Bao; D C Qian
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

2.  Selection criteria for hepatectomy in patients with hepatocellular carcinoma classified as Child-Pugh class B.

Authors:  Shintaro Kuroda; Hirotaka Tashiro; Tsuyoshi Kobayashi; Akihiko Oshita; Hironobu Amano; Hideki Ohdan
Journal:  World J Surg       Date:  2011-04       Impact factor: 3.352

3.  Long-term follow-up outcome of patients undergoing radiofrequency ablation for unresectable hepatocellular carcinoma.

Authors:  Junji Machi; Racquel S Bueno; Linda L Wong
Journal:  World J Surg       Date:  2005-11       Impact factor: 3.352

4.  Cytoreduction and sequential resection for surgically verified unresectable hepatocellular carcinoma: evaluation with analysis of 72 patients.

Authors:  Z Y Tang; Y Q Uy; X D Zhou; Z C Ma; J Z Lu; Z Y Lin; K D Liu; S L Ye; B H Yang; H W Wang
Journal:  World J Surg       Date:  1995 Nov-Dec       Impact factor: 3.352

5.  Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy?

Authors:  René Adam; Daniel Azoulay; Denis Castaing; Rony Eshkenazy; Gérard Pascal; Kentaro Hashizume; Didier Samuel; Henri Bismuth
Journal:  Ann Surg       Date:  2003-10       Impact factor: 12.969

6.  Treatment of unresectable primary liver cancer: with reference to cytoreduction and sequential resection.

Authors:  Z Y Tang; Y Q Yu; X D Zhou; Z C Ma; B H Yang; Z Y Lin; J Z Lu; K D Liu; Z Fan; Z C Zeng
Journal:  World J Surg       Date:  1995 Jan-Feb       Impact factor: 3.352

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.